Cancer Communications | Professor Shi Yanxia and Professor An Xin’s Team Explores a New Post-Resistance Treatment Strategy for Advanced Urothelial Carcinoma

Cancer Communications | Professor Shi Yanxia and Professor An Xin’s Team Explores a New Post-Resistance Treatment Strategy for Advanced Urothelial Carcinoma

On April 21, 2026, Professor Shi Yanxia and Professor An Xin’s team from Sun Yat-sen University Cancer Center published their latest findings in the international journal Cancer Communications under the title “Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study.”
“Deep Dive Debate” | After Achieving pCR with Immunotherapy in TNBC, Should Adjuvant Immunotherapy Be Continued or Stopped?

“Deep Dive Debate” | After Achieving pCR with Immunotherapy in TNBC, Should Adjuvant Immunotherapy Be Continued or Stopped?

With the success of landmark clinical studies such as KEYNOTE-522, neoadjuvant treatment for early-stage triple-negative breast cancer (TNBC) has fully entered the era of immunotherapy combined with chemotherapy. While this strategy has significantly improved pathological complete response (pCR) rates and delivered substantial survival benefits, it has also raised one of the most debated questions in current clinical practice:
2026 CSCO BC Guideline Highlights | Professor Chunfang Hao: Key Updates in Salvage Endocrine Therapy for HR-Positive Advanced Breast Cancer — Multi-Directional Strategies, Precision Assessment, Optimized Combinations, and Sequential Multi-Target Therapy

2026 CSCO BC Guideline Highlights | Professor Chunfang Hao: Key Updates in Salvage Endocrine Therapy for HR-Positive Advanced Breast Cancer — Multi-Directional Strategies, Precision Assessment, Optimized Combinations, and Sequential Multi-Target Therapy

The 2026 National Breast Cancer Conference was held in Beijing from April 10–12, during which the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2026 (CSCO BC Guidelines 2026) underwent major updates. At the meeting, Professor Chunfang Hao from Tianjin Medical University Cancer Institute and Hospital delivered a comprehensive overview of the latest advances in the management of HR-positive breast cancer.
2026 CSCO Guidelines Conference | Academician Jinming Yu: Strengthening China-Based Evidence, Advancing Global Guideline Outreach, and Bringing Standardized Cancer Care to the Grassroots Level

2026 CSCO Guidelines Conference | Academician Jinming Yu: Strengthening China-Based Evidence, Advancing Global Guideline Outreach, and Bringing Standardized Cancer Care to the Grassroots Level

The 2026 Chinese Society of Clinical Oncology (CSCO) Guidelines Conference was grandly held in Harbin from April 24–25. Bringing together more than a thousand experts, the meeting focused on guideline updates, intelligent healthcare, and multidisciplinary collaboration, with a strong emphasis on extending standardized cancer care to grassroots medical institutions and narrowing regional disparities in oncology practice.
2026 HOT Conference | Professor Zhenzhen Liu: From Live Surgical Demonstrations to Specialty Center Development — Advancing Breast Cancer Care on Multiple Fronts

2026 HOT Conference | Professor Zhenzhen Liu: From Live Surgical Demonstrations to Specialty Center Development — Advancing Breast Cancer Care on Multiple Fronts

With the warmth of spring invigorating the Central Plains, the 18th Northern Breast Cancer HOT Conference was successfully held in Zhengzhou from April 16–18, 2026. During the meeting, Oncology Frontier conducted an exclusive interview with the conference chair, Professor Zhenzhen Liu from Henan Cancer Hospital. In the interview, she discussed the conference’s major highlights, the development of specialty center models, and both the challenges and practical value of promoting multidisciplinary team (MDT) care at the grassroots level.
CSCO BC 10th Anniversary Tribute | Professor Yongmei Yin: A New Starting Point, A New Mission — CSCO BC Leading China’s Breast Cancer Care into a New Era of High-Quality Development

CSCO BC 10th Anniversary Tribute | Professor Yongmei Yin: A New Starting Point, A New Mission — CSCO BC Leading China’s Breast Cancer Care into a New Era of High-Quality Development

As the Breast Cancer Committee of the Chinese Society of Clinical Oncology (CSCO BC) marks its 10th anniversary, the 2026 National Breast Cancer Conference was grandly convened. More than an academic gathering, this conference served as a comprehensive review of CSCO BC’s decade-long journey and a blueprint for the future of breast cancer care in China.
AOT 2026 · Boundless Dialogue | Professors William Hwang Ying Khee and Yanmin Zhao Explore the Balance Between GVL and GVHD

AOT 2026 · Boundless Dialogue | Professors William Hwang Ying Khee and Yanmin Zhao Explore the Balance Between GVL and GVHD

To comprehensively improve public health and strengthen strategies for the prevention and treatment of major diseases, medical innovation and international collaboration have become key drivers of clinical progress. Against this backdrop, the 2026 Beijing International Hematopoietic Stem Cell Transplantation Conference (AOT) was successfully held in Beijing from April 24 to 25, 2026. Organized by the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care and hosted by the National Clinical Research Center for Hematologic Diseases and the Peking University Institute of Hematology, this year’s conference centered on the theme “The Art of Transplantation.” The event brought together leading global experts in hematology to discuss cutting-edge innovations and emerging trends in hematopoietic stem cell transplantation.
AOT 2026 | Professor Andrew Artz: Current Landscape, Challenges, and Optimization Strategies for Hematopoietic Stem Cell Transplantation in Older Adults in the United States

AOT 2026 | Professor Andrew Artz: Current Landscape, Challenges, and Optimization Strategies for Hematopoietic Stem Cell Transplantation in Older Adults in the United States

To comprehensively improve public health and strengthen strategies for the prevention and treatment of major diseases, medical innovation and international collaboration have become key drivers of clinical progress. Against this backdrop, the 2026 Beijing International Hematopoietic Stem Cell Transplantation Conference (AOT) was successfully held in Beijing from April 24 to 25, 2026. Organized by the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care and hosted by the National Clinical Research Center for Hematologic Diseases and the Peking University Institute of Hematology, this year’s conference centered on the theme “The Art of Transplantation.” The meeting brought together leading hematology experts from around the world to discuss cutting-edge innovations and future trends in hematopoietic stem cell transplantation.
AOT 2026 | Professor Hans H. Hirsch: Comprehensive Infection Prevention and Clinical Management for Post-Transplant Reintegration Into the Community

AOT 2026 | Professor Hans H. Hirsch: Comprehensive Infection Prevention and Clinical Management for Post-Transplant Reintegration Into the Community

To comprehensively improve public health and strengthen strategies for the prevention and treatment of major diseases, medical innovation and international collaboration have become key drivers of clinical progress. Against this backdrop, the 2026 Beijing International Hematopoietic Stem Cell Transplantation Conference (AOT) was successfully held in Beijing from April 24 to 25, 2026. Organized by the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care and hosted by the National Clinical Research Center for Hematologic Diseases and the Peking University Institute of Hematology, this year’s conference centered on the theme “The Art of Transplantation.” The meeting brought together leading hematology experts from around the world to discuss cutting-edge innovations and emerging trends in hematopoietic stem cell transplantation.